BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35950215)

  • 1.
    Jian X; Xu L; Zhao J; Wang Y; Zhou W; Xie L
    Mol Ther Nucleic Acids; 2022 Sep; 29():285-295. PubMed ID: 35950215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer.
    Ren Y; Cherukuri Y; Wickland DP; Sarangi V; Tian S; Carter JM; Mansfield AS; Block MS; Sherman ME; Knutson KL; Lin Y; Asmann YW
    Oncoimmunology; 2020; 9(1):1744947. PubMed ID: 32523802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of genomic alterations and neoantigens and analysis of immune infiltration identified therapeutic and prognostic biomarkers in adenocarcinoma at the gastroesophageal junction.
    Lao Y; Wang Y; Yang J; Liu T; Ma Y; Luo Y; Sun Y; Li K; Zhao X; Niu X; Xi Y; Zhong C
    Front Oncol; 2022; 12():941868. PubMed ID: 36439494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A New Pipeline to Predict and Confirm Tumor Neoantigens Predict Better Response to Immune Checkpoint Blockade.
    Lazdun Y; Si H; Creasy T; Ranade K; Higgs BW; Streicher K; Durham NM
    Mol Cancer Res; 2021 Mar; 19(3):498-506. PubMed ID: 33257508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies.
    Lo AA; Wallace A; Oreper D; Lounsbury N; Havnar C; Pechuan-Jorge X; Wu TD; Bourgon R; Jones R; Krogh K; Yang GY; Zill OA
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neodb: a comprehensive neoantigen database and discovery platform for cancer immunotherapy.
    Wu T; Chen J; Diao K; Wang G; Wang J; Yao H; Liu XS
    Database (Oxford); 2023 Jun; 2023():. PubMed ID: 37311149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoantigen landscape in metastatic nasopharyngeal carcinoma.
    Lin M; Zhang XL; You R; Yang Q; Zou X; Yu K; Liu YP; Zou RH; Hua YJ; Huang PY; Wang J; Zhao Q; Jiang XB; Tang J; Gu YK; Yu T; He GP; Xie YL; Wang ZQ; Liu T; Chen SY; Zuo ZX; Chen MY
    Theranostics; 2021; 11(13):6427-6444. PubMed ID: 33995666
    [No Abstract]   [Full Text] [Related]  

  • 8. Systematically Characterizing A-to-I RNA Editing Neoantigens in Cancer.
    Zhou C; Wei Z; Zhang L; Yang Z; Liu Q
    Front Oncol; 2020; 10():593989. PubMed ID: 33363023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GNIFdb: a neoantigen intrinsic feature database for glioma.
    Li W; Sun T; Li M; He Y; Li L; Wang L; Wang H; Li J; Wen H; Liu Y; Chen Y; Fan Y; Xin B; Zhang J
    Database (Oxford); 2022 Feb; 2022():. PubMed ID: 35150127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The frequency of neoantigens per somatic mutation rather than overall mutational load or number of predicted neoantigens per se is a prognostic factor in ovarian clear cell carcinoma.
    Matsushita H; Hasegawa K; Oda K; Yamamoto S; Nishijima A; Imai Y; Asada K; Ikeda Y; Karasaki T; Fujiwara K; Aburatani H; Kakimi K
    Oncoimmunology; 2017; 6(8):e1338996. PubMed ID: 28920005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of shared neoantigens in esophageal carcinoma by the combination of comprehensive analysis of genomic data and in silico neoantigen prediction.
    Yuan Y; Chen C; Liu S; Xiong H; Huang Y; Zhang X; Zhang X; Li B
    Cell Immunol; 2022 Jul; 377():104537. PubMed ID: 35636066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.
    Yu Y; Zhang J; Ni L; Zhu Y; Yu H; Teng Y; Lin L; Xue Z; Xue X; Shen X; Song H; Su X; Sun W; Cai Z
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-11. PubMed ID: 33689574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes.
    Lu T; Wang S; Xu L; Zhou Q; Singla N; Gao J; Manna S; Pop L; Xie Z; Chen M; Luke JJ; Brugarolas J; Hannan R; Wang T
    Sci Immunol; 2020 Feb; 5(44):. PubMed ID: 32086382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction and validation of an immunoediting-based optimized neoantigen load (ioTNL) model to predict the response and prognosis of immune checkpoint therapy in various cancers.
    Su X; Jin H; Wang J; Lu H; Gu T; Gao Z; Li M
    Aging (Albany NY); 2022 May; 14(10):4586-4605. PubMed ID: 35613927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PGNneo: A Proteogenomics-Based Neoantigen Prediction Pipeline in Noncoding Regions.
    Tan X; Xu L; Jian X; Ouyang J; Hu B; Yang X; Wang T; Xie L
    Cells; 2023 Mar; 12(5):. PubMed ID: 36899918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profiling of hepatocellular carcinoma neoantigens reveals immune microenvironment and clonal evolution related patterns.
    Li Z; Chen G; Cai Z; Dong X; He L; Qiu L; Zeng Y; Liu X; Liu J
    Chin J Cancer Res; 2021 Jun; 33(3):364-378. PubMed ID: 34321833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma.
    Miller A; Asmann Y; Cattaneo L; Braggio E; Keats J; Auclair D; Lonial S; ; Russell SJ; Stewart AK
    Blood Cancer J; 2017 Sep; 7(9):e612. PubMed ID: 28937974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization.
    Müller M; Gfeller D; Coukos G; Bassani-Sternberg M
    Front Immunol; 2017; 8():1367. PubMed ID: 29104575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low T-cell Receptor Diversity, High Somatic Mutation Burden, and High Neoantigen Load as Predictors of Clinical Outcome in Muscle-invasive Bladder Cancer.
    Choudhury NJ; Kiyotani K; Yap KL; Campanile A; Antic T; Yew PY; Steinberg G; Park JH; Nakamura Y; O'Donnell PH
    Eur Urol Focus; 2016 Oct; 2(4):445-452. PubMed ID: 28723478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.